Weight-Loss Drugs Like Ozempic and Mounjaro Linked to Hair Loss, Review Finds

The weight-loss drugs semaglutide and tirzepatide have been linked to hair loss in a systematic review — adding a cosmetic concern to a class already under intense scrutiny.

The 2026 review screened 133 studies and analysed 24 meeting its criteria. Among the GLP-1 class, semaglutide and tirzepatide showed the highest incidence and the strongest signals in drug-safety monitoring databases.

How big the risk is

Compared with patients starting metformin, those beginning semaglutide had a 43% higher relative risk of non-scarring hair loss (risk ratio 1.43), and those on tirzepatide a 68% higher risk (risk ratio 1.68).

Notably, the older GLP-1 drugs dulaglutide and liraglutide showed no significant increase.

Regulators are seeing it too: in 2026 the UK’s medicines regulator logged 399 hair-loss reports tied to tirzepatide and 148 tied to semaglutide.

Why the older drugs matter to the interpretation

The finding that dulaglutide and liraglutide show no increase is the most informative detail in the review.

If hair loss were a property of GLP-1 receptor activation as such, every drug in the class would produce it. That the two agents causing the most weight loss show the signal, and the two causing least do not, points to weight loss rather than the receptor.

Tirzepatide, which produces the greatest weight loss, was also most often linked to telogen effluvium — the pattern most associated with rapid physiological change.

The dose-response across drugs, in effect, does the work an experiment would.

What telogen effluvium is

The most common patterns were androgenetic alopecia and telogen effluvium, a temporary shedding often triggered by rapid weight loss or physiological stress.

Hair follicles cycle between a growth phase lasting years and a resting phase ending in shedding. Normally the population is unsynchronised, so shedding is gradual and unnoticed.

A systemic stress — rapid weight loss, illness, surgery, childbirth, nutritional deficiency — can push many follicles into the resting phase simultaneously. They then shed together, typically two to four months later, which is why the hair loss appears well after the triggering event and often after the person has begun feeling better.

Hair growth is metabolically expensive and not essential to survival, so follicles are among the first tissues down-prioritised when the body registers deprivation.

Whether it grows back

These are non-scarring forms, meaning the follicles stay intact and hair can regrow once the body stabilises.

That distinction is the substantive reassurance. Scarring alopecias destroy the follicle permanently and no treatment restores hair from a follicle that no longer exists. Non-scarring loss is a shift in cycling, and the follicle resumes when the trigger resolves.

Recovery typically takes months, since the follicle must re-enter growth phase and produce visible length — which is slower than the shedding was.

What this means for patients

Hair loss is distressing but, in this context, typically temporary and cosmetic rather than dangerous. It may be driven as much by the speed of weight loss as by the drug itself.

Practical implications follow from that. Adequate protein intake matters, since hair is largely protein and deficiency worsens shedding, and rapid loss on appetite-suppressing drugs makes inadequate intake likely. Slower dose escalation may reduce the effect.

How to read pharmacovigilance report counts

The regulator figures — 399 reports for tirzepatide, 148 for semaglutide — are worth interpreting carefully, because raw counts from spontaneous reporting systems mislead easily.

These systems collect reports submitted voluntarily by patients and clinicians. They have no denominator: nobody knows how many people took the drug, so a count cannot be converted into a rate.

Reporting is also heavily influenced by attention. A drug in the news generates more reports for the same underlying rate, because people who would otherwise attribute a symptom to something else now connect it to the medication. Media coverage of a suspected side effect reliably produces a surge in reports of that side effect.

Prescription volume matters too. If tirzepatide is more widely prescribed than semaglutide in a given market, more reports follow without any difference in risk.

What these systems are good at is detecting signals nobody was looking for — an unexpected pattern appearing across many independent reports. Quantifying risk requires the controlled comparison the review supplies, which is why the risk ratios against metformin carry the weight here and the report counts are context rather than evidence.

Anyone worried should talk to their prescriber before stopping treatment — abruptly quitting has its own consequences, including near-universal weight regain. General information, not medical advice.